NU7441 (KU-57788)

Catalog No.S2638

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.

Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

NU7441 (KU-57788) Chemical Structure

NU7441 (KU-57788) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

NU7441 (KU-57788) is available in the following compound libraries:

DNA-PK Inhibitors with Unique Features

  • Non-specific DNA-PK Inhibitor

    PI-103 DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.

  • Most Potent DNA-PK Inhibitor

    PIK-75 DNA-PK, IC50=2 nM.

  • Newest DNA-PK Inhibitor

    KU-0060648 Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Classic DNA-PK Inhibitor

    NU7026 Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Product Information

  • Compare DNA-PK Inhibitors
    Compare DNA-PK Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.
Targets DNA-PK [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3K [1]
(Cell-free assay)
ATM [1]
(Cell-free assay)
ATR [1]
(Cell-free assay)
IC50 14 nM 1.7 μM 5 μM >100 μM >100 μM
In vitro NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. [2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. [3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. [4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. [5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1770MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TwXWlEPTB;MD6wNlE1OyEQvF2=MUfTRW5ITVJ?
A172NYnjWnVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1SwOWlEPTB;MD6xOVMyPiEQvF2=MnHZV2FPT0WU
NCI-H526MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH74cXdKSzVyPUCuNlg1ODdizszNM3\Wc3NCVkeHUh?=
HDLM-2NF3UXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjRU2VqUUN3ME2wMlMzOzR3IN88US=>MYTTRW5ITVJ?
HuO-3N1NVTI[|dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zvZ2lEPTB;MD60OlY{PiEQvF2=M370SXNCVkeHUh?=
NCI-SNU-1NUTaVnd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLETWM2OD1yLk[wPVk1KM7:TR?=M4TGbHNCVkeHUh?=
SK-N-ASMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnz5TWM2OD1yLk[yNlE3KM7:TR?=MkDNV2FPT0WU
LoVoM1nnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTBwOE[3OFkh|ryPNYHJeYRsW0GQR1XS
LAMA-84M{DNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HCPWlEPTB;MD65PFg{OyEQvF2=M{DuRnNCVkeHUh?=
CTB-1NYXoNFlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTFwMUG1OFYh|ryPNFzHfJVUSU6JRWK=
KP-N-YSNEDmbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFwMUSyN|Eh|ryPNETndFFUSU6JRWK=
HHM1vYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvDR4JqUUN3ME2xMlE5ODl|IN88US=>NXq3ZoRiW0GQR1XS
CHL-1NUPpS29QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTFwMkGzOlgh|ryPMWXTRW5ITVJ?
NB7MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwMkS3OFUh|ryPM4TLNHNCVkeHUh?=
HL-60M3zKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTrTWM2OD1zLkO4NVkh|ryPMVTTRW5ITVJ?
639-VM3nwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFW1WmRKSzVyPUGuOFQyOjhizszNMYDTRW5ITVJ?
NCI-H1793MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37YNGlEPTB;MT60OVg1KM7:TR?=MnPpV2FPT0WU
NEC8NEjzVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnf0TWM2OD1zLkW1N|Uh|ryPMXjTRW5ITVJ?
PA-1NUG3OYtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1qzSGlEPTB;MT61PFI6PCEQvF2=NYT3OWxmW0GQR1XS
D-423MGMnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\3V2lEPTB;MT62PVM3OSEQvF2=MoC5V2FPT0WU
NCI-H292MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWm1TmxrUUN3ME2xMlc1ODF|IN88US=>NUDpSY5tW0GQR1XS
SK-MEL-1M{fDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;CTlQ1UUN3ME2xMlc6PDd7IN88US=>MkLPV2FPT0WU
LB2241-RCCMnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmKwTWM2OD1{LkG0NVQ3KM7:TR?=MX;TRW5ITVJ?
SK-MEL-3MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJwMU[0PUDPxE1?MkC3V2FPT0WU
MHH-PREB-1NV7UcmhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJwMU[2NFkh|ryPMXHTRW5ITVJ?
BFTC-905NX;velBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4K2d2lEPTB;Mj6xOlY5PyEQvF2=NFnsXJVUSU6JRWK=
Ramos-2G6-4C10M2rxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LEPWlEPTB;Mj6xPVkxQSEQvF2=NVzyWmI4W0GQR1XS
G-361NXKyTHFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3Ze4Y3UUN3ME2yMlIyPjhizszNNEPnTmNUSU6JRWK=
MOLT-4MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFm4e29KSzVyPUKuNlE5QDhizszNNUnH[oJMW0GQR1XS
DELMn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHi4fplKSzVyPUKuN|U2PjRizszNNYTKSFdsW0GQR1XS
MV-4-11Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXwTWM2OD1{LkO3N|kh|ryPNUPtcYxtW0GQR1XS
SK-NEP-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHoTWM2OD1{LkO4O|g{KM7:TR?=MomzV2FPT0WU
RS4-11NFH4e4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXuUHp7UUN3ME2yMlU3ODJ|IN88US=>M37oNnNCVkeHUh?=
HuH-7M3r3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDNTWM2OD1{LkW2O|AzKM7:TR?=NWDSfohOW0GQR1XS
A101DM{PTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTJwNkGzN|gh|ryPMWDTRW5ITVJ?
KG-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPPTWM2OD1{Lk[3PVI1KM7:TR?=NXTDV21UW0GQR1XS
KALS-1NYO2Z251T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn[5TWM2OD1{Lk[5OlM{KM7:TR?=NWKxU5Z1W0GQR1XS
VMRC-RCZMoj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M16ye2lEPTB;Mj63O|MzQCEQvF2=MnPJV2FPT0WU
SK-UT-1MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HGUWlEPTB;Mz6xOVMyKM7:TR?=MXnTRW5ITVJ?
SW962NX3mOoNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHG3d3BKSzVyPUOuNlA{PTJizszNM1\5NXNCVkeHUh?=
DBTRG-05MGMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnVVXhKSzVyPUOuNlgxQDVizszNMof3V2FPT0WU
PANC-08-13MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDISWVXUUN3ME2zMlQyOjd6IN88US=>MmH2V2FPT0WU
QIMR-WILNVy5SZE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHVdWd[UUN3ME2zMlQyOzRzIN88US=>NHHIfGFUSU6JRWK=
SK-MEL-30NUOwUHZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLyTWM2OD1|LkSyOVk5KM7:TR?=M2TFOXNCVkeHUh?=
697NWjzVYQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHtTWM2OD1|LkS0PVk{KM7:TR?=MYXTRW5ITVJ?
NYM3K4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjBO2ZrUUN3ME2zMlQ2ODJ{IN88US=>NXy2Npc4W0GQR1XS
ES7MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzUTWM2OD1|LkS2O|I6KM7:TR?=MlLXV2FPT0WU
JVM-3NFrlXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHJe4FKSzVyPUOuOFgxPzdizszNNGDkVoFUSU6JRWK=
U031M1rOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\oUWQ4UUN3ME2zMlU6OzZ6IN88US=>MmPlV2FPT0WU
BHT-101NYn0TVZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHOwSHNKSzVyPUOuOVk6QDVizszNNX\F[2NXW0GQR1XS
8305CMnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTNwNkG3N|Yh|ryPNEDoPVdUSU6JRWK=
MG-63NHzXNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3UTWM2OD1|Lk[yOlc3KM7:TR?=NYexXm43W0GQR1XS
NOS-1NUPhWJM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLjTWM2OD1|Lk[1N|EzKM7:TR?=NFrsdolUSU6JRWK=
YH-13NX7ldXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljjTWM2OD1|Lki3NVg6KM7:TR?=NV22NllqW0GQR1XS
LXF-289M3TJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HZZWlEPTB;Mz65NVA1OSEQvF2=NXu0OYZXW0GQR1XS
GOTONHfte4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTNwOUG0PUDPxE1?NHfQZ4xUSU6JRWK=
EKVXMorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1e5b2lEPTB;ND6yNlUzPCEQvF2=MVTTRW5ITVJ?
CAL-51M1HJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTRwMkS4OVQh|ryPMV7TRW5ITVJ?
AN3-CAM1jxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlf3TWM2OD12LkK1PFE{KM7:TR?=NWT4c4NNW0GQR1XS
IA-LMMn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PkfmlEPTB;ND6yO|k{PSEQvF2=MV\TRW5ITVJ?
KU-19-19M3q5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH64bYVKSzVyPUSuN|I6OjFizszNM3nr[XNCVkeHUh?=
A704NX7BNFBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVj3ZnpRUUN3ME20MlQxQDh6IN88US=>NW[1OoVrW0GQR1XS
RH-18M17DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2i4SWlEPTB;ND60OFk2OyEQvF2=NIXlT2pUSU6JRWK=
IST-MEL1NWHYfYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nveGlEPTB;ND61PFI3OyEQvF2=MVHTRW5ITVJ?
LU-134-AMlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjITm5KSzVyPUSuOVk3QDVizszNMV;TRW5ITVJ?
SF126M33pS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnBUopkUUN3ME20MlYxPzF3IN88US=>MWPTRW5ITVJ?
EFO-27NV\lS4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1y3V2lEPTB;ND62OlUzPSEQvF2=Mn3vV2FPT0WU
SN12CMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUKz[5VqUUN3ME20MlcyQDl6IN88US=>MnrCV2FPT0WU
L-363M2\IdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDITWM2OD12Lke3NVE3KM7:TR?=MofuV2FPT0WU
MEL-HOMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnroTWM2OD12Lke3PVg6KM7:TR?=MW\TRW5ITVJ?
TYK-nuM2T2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTRwOECxNlgh|ryPNX2wZZBJW0GQR1XS
MDA-MB-415M2f6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULXXmh7UUN3ME21MlAxOzF2IN88US=>MUnTRW5ITVJ?
HCC70MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTzTWM2OD13LkCzPVM6KM7:TR?=NXraUnJpW0GQR1XS
IGROV-1Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHnO5VKSzVyPUWuNlUzQTJizszNMnuwV2FPT0WU
NCI-H1355MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfzb5NiUUN3ME21MlI6PiEQvF2=M3vVPXNCVkeHUh?=
23132-87NY\RbGQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;FTWM2OD13LkOyNFI1KM7:TR?=MnjEV2FPT0WU
NB69M1rBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTVwM{K0NkDPxE1?MmnJV2FPT0WU
HSC-2NX3INY5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jiRWlEPTB;NT60NVc4OyEQvF2=NHXIcppUSU6JRWK=
KYSE-410MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzSXHVKSzVyPUWuOFc3OzZizszNNULVXFVkW0GQR1XS
GCIYNXG4bYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DFeGlEPTB;NT61NVM4QCEQvF2=NH;pZZJUSU6JRWK=
A427NVTEW5B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mom0TWM2OD13LkWzOlYyKM7:TR?=NFTaeIJUSU6JRWK=
ChaGo-K-1Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDCVJlKSzVyPUWuOVY2QTlizszNMnjlV2FPT0WU
PFSK-1MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTVwNkKxPVQh|ryPM4ThOHNCVkeHUh?=
MLMAMoq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHnfIhKSzVyPUWuPFM3ODZizszNM1\5SHNCVkeHUh?=
RVH-421NHnUSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M362OmlEPTB;Nj6wO|M{QCEQvF2=MYjTRW5ITVJ?
LB1047-RCCM3jQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfp[pVKSzVyPU[uNVc2OjJizszNMn;aV2FPT0WU
MHH-NB-11NI\LZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGqyfGVKSzVyPU[uN|I4OjFizszNMU\TRW5ITVJ?
J-RT3-T3-5MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTZwNkOyPVEh|ryPNInCR4FUSU6JRWK=
UM-UC-3M2r3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjpTWM2OD14Lk[0N|M1KM7:TR?=MojGV2FPT0WU
IST-SL1MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIr5bXdKSzVyPU[uOlk{PjlizszNMXPTRW5ITVJ?
NB14NGTjR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGSxdplKSzVyPU[uO|k4PjFizszNMWXTRW5ITVJ?
NBsusSRNUCzXWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PD[GlEPTB;Nj64NlUxOiEQvF2=MkK2V2FPT0WU
D-263MGNE\sUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTZwOUGwOlgh|ryPMVfTRW5ITVJ?
NCI-H2347Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnkTWM2OD14LkmzNlE{KM7:TR?=NX22PIcxW0GQR1XS
ES8NWO0OWRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTZwOUe1PFgh|ryPNGLve5RUSU6JRWK=
786-0MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTdwMEm3PFYh|ryPNGT0UZdUSU6JRWK=
EPLC-272HMmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILkeoFKSzVyPUeuNVYzPDZizszNMVLTRW5ITVJ?
CAPAN-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nE[WlEPTB;Nz6yOFM2QSEQvF2=NGTLUVlUSU6JRWK=
NCI-H82NVr2NnJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7YTWM2OD15LkK2OlU6KM7:TR?=MkDMV2FPT0WU
G-402NXnySFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmT1TWM2OD15LkOwNFUyKM7:TR?=NFLPZoVUSU6JRWK=
SW982NXXm[|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4GwSWlEPTB;Nz6zNFIxOyEQvF2=NETqeopUSU6JRWK=
OVCAR-4Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7pfWFKSzVyPUeuN|E{OjhizszNNHn5d|NUSU6JRWK=
KARPAS-299MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrnTWM2OD15LkOyOlIzKM7:TR?=MnLIV2FPT0WU
MIA-PaCa-2NVnZRW9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7yTWM2OD15LkO2PFI{KM7:TR?=NXLHc5FDW0GQR1XS
AU565M{HQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonITWM2OD15LkW5PFM{KM7:TR?=NEXJN2lUSU6JRWK=
GAMGMljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXBWYpKSzVyPUeuOlQyOzFizszNM4C5OHNCVkeHUh?=
HuO9M37Hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;KVWlEPTB;Nz63NVc1OyEQvF2=MVHTRW5ITVJ?
ACNNUDHXIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjBSmlHUUN3ME23Mlc1OzNizszNMknWV2FPT0WU
RO82-W-1Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjwTHlKSzVyPUeuO|Q2OzNizszNNHfyW4hUSU6JRWK=
NKM-1NH20R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTdwN{S5OVUh|ryPMVrTRW5ITVJ?
CAL-12TM3TSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTdwOUSzOVIh|ryPNGn5WoNUSU6JRWK=
FADUMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzZN3RKSzVyPUiuNFM3PTRizszNMW\TRW5ITVJ?
NCI-H28NXv4e4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRThwMU[5OlIh|ryPMYPTRW5ITVJ?
LCLC-97TM1M175XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfuc21KSzVyPUiuNlEyOjJizszNMUTTRW5ITVJ?
CHP-134NYW1cW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRThwMkSxPFUh|ryPNUXMUpJTW0GQR1XS
HT-1080NVu0UoJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnJV4NLUUN3ME24MlI2ODl|IN88US=>NYLYcYlWW0GQR1XS
PC-3NFHlSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnhXlRSUUN3ME24MlI4Ozl{IN88US=>NGmySoRUSU6JRWK=
SNU-449NED5NmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmO4TWM2OD16LkK3PVMh|ryPNU\VSmFpW0GQR1XS
VA-ES-BJNETQeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRThwM{S2PFYh|ryPM1;i[HNCVkeHUh?=
HTNEnxbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rvfWlEPTB;OD6zOlQ6KM7:TR?=Mn3XV2FPT0WU
HOSMoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlWzTWM2OD16LkO3OVg6KM7:TR?=M2XoTnNCVkeHUh?=
KNS-62M4\KeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXKOJNKSzVyPUiuN|c4PjJizszNMmK5V2FPT0WU
OAW-42Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnmb25KSzVyPUiuPVU6PjRizszNNWLOeVZoW0GQR1XS
A549M2r2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1S3UmlEPTB;OT6wPVYyOiEQvF2=NHnlbIJUSU6JRWK=
CAKI-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEG2TlFKSzVyPUmuNVY3OSEQvF2=MmHJV2FPT0WU
HCC1937M1T5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjZcYJKSzVyPUmuOlk5PjVizszNMVPTRW5ITVJ?
GI-ME-NM3\SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofCTWM2OD17LkewNVM4KM7:TR?=MXXTRW5ITVJ?
DU-4475NYjj[WU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7tOodKSzVyPUmuPVY6OzlizszNNGjRdHpUSU6JRWK=
EM-2NILDUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoqzTWM2OD1zMD6yOFI3KM7:TR?=MoLGV2FPT0WU
NCI-H1755M173VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTFyLkK0Nlgh|ryPNVz6XI5oW0GQR1XS
NCI-H1437NXXJO44zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;kbVNCUUN3ME2xNE42PzJ3IN88US=>NGHDUopUSU6JRWK=
VM-CUB-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\GWVdlUUN3ME2xNE43OTZ2IN88US=>MWjTRW5ITVJ?
A2058MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVi2bFg3UUN3ME2xNE43PDB2IN88US=>MmXoV2FPT0WU
BPH-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLTUVFKSzVyPUGwMlcyPDVizszNMmLmV2FPT0WU
NB5NYraTo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fQTWlEPTB;MUCuO|U2QSEQvF2=NFHTXVVUSU6JRWK=
G-401MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\DTWM2OD1zMD63OlI3KM7:TR?=M2jz[nNCVkeHUh?=
CAL-72MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTFyLkiwPVQh|ryPMWTTRW5ITVJ?
SK-MEL-28NEXKNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjWdoxKSzVyPUGwMlgzODJizszNNEfmO2tUSU6JRWK=
C32MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfJNFF2UUN3ME2xNE45OzR5IN88US=>NVvvcIY6W0GQR1XS
NCI-H1155NX\iXohxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3K2UmlEPTB;MUCuPFM4PiEQvF2=NE\vR2tUSU6JRWK=
BB49-HNCNGD4d5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\tXY9OUUN3ME2xNE45PTh4IN88US=>MVLTRW5ITVJ?
GMS-10M3XkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoezTWM2OD1zMD64PVcyKM7:TR?=NGLPfVlUSU6JRWK=
K5NVTxcnI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYm3cIJHUUN3ME2xNE46ODdzIN88US=>NHHFZ|hUSU6JRWK=
OS-RC-2M1\0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrCfY9KSzVyPUGxMlA2PTlizszNNEPXOZJUSU6JRWK=
HTC-C3MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTFzLkC3NVQh|ryPM3LEXHNCVkeHUh?=
LB996-RCCNYDjO5NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmq0TWM2OD1zMT6wO|I{KM7:TR?=M3fVXXNCVkeHUh?=
NCI-H1563MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjNc4pkUUN3ME2xNU4yODFzIN88US=>M2\PNnNCVkeHUh?=
CAL-54NFXo[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1P6S2lEPTB;MUGuOFgyOSEQvF2=M4XhR3NCVkeHUh?=
WM-115NWSz[3VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIC0cYZKSzVyPUGxMlY5OjRizszNNFP1V4VUSU6JRWK=
COLO-684NX34S45RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIeyW4NKSzVyPUGxMlczPjdizszNM3nYfHNCVkeHUh?=
HOP-62MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fkNmlEPTB;MUGuO|UxQCEQvF2=MUfTRW5ITVJ?
NCI-H650NED5WXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHpNJpYUUN3ME2xNU45QTZzIN88US=>MXzTRW5ITVJ?
TE-11NVP1bVNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nxUGlEPTB;MUGuPVMyPSEQvF2=MnHkV2FPT0WU
COLO-679NGnEXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjkfoRsUUN3ME2xNU46PDZizszNNWixV2VpW0GQR1XS
FTC-133M{DqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXNTWM2OD1zMj6wNFc3KM7:TR?=NGrCcm5USU6JRWK=
D-283MEDM3:0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTF{LkC1Olkh|ryPMmHmV2FPT0WU
SK-PN-DWM37ZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYr2fHNzUUN3ME2xNk4yQTB{IN88US=>NX2yN25EW0GQR1XS
BALL-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoP2TWM2OD1zMj6yOlYzKM7:TR?=Mk[wV2FPT0WU
GT3TKBM3H6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFS5dlRKSzVyPUGyMlMxPzRizszNM1ezVnNCVkeHUh?=
HOP-92NWLOfZN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHT6W3VKSzVyPUGyMlUzOzNizszNM2PyfHNCVkeHUh?=
M14NW\OeYdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\vUWgxUUN3ME2xN{4xOzN3IN88US=>NGLmXnVUSU6JRWK=
SKG-IIIaNXrLUpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF|LkC1OVQh|ryPMVTTRW5ITVJ?
BeckerMkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnj0TWM2OD1zMz6wOVgh|ryPNHHoWmhUSU6JRWK=
ES5MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTF|LkGzOVYh|ryPNHTqXoVUSU6JRWK=
NCI-H2030MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrTUG5KSzVyPUGzMlIxPjJizszNNW\uNnBLW0GQR1XS
SNU-423MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTF|LkO4NUDPxE1?MVzTRW5ITVJ?
CP50-MEL-BMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\Vd2tXUUN3ME2xN{43OjN{IN88US=>M1zZUHNCVkeHUh?=
NCI-H1092MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXwTWM2OD1zMz63OFc2KM7:TR?=MVnTRW5ITVJ?
8-MG-BANVzydolRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLpVpVbUUN3ME2xN{44PTF|IN88US=>NH;iSI9USU6JRWK=
CAL-27MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rySWlEPTB;MUSuNFczPyEQvF2=MVvTRW5ITVJ?
AGSM4TkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTF2LkGzNVkh|ryPNEPSWZRUSU6JRWK=
MZ2-MELNWexd2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLqTWM2OD1zND6xOFg5KM7:TR?=NWjJZ2JUW0GQR1XS
BFTC-909MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPBR4FKSzVyPUG0MlUxPTVizszNM1facnNCVkeHUh?=
D-566MGM{TDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3qTWM2OD1zND63O|A3KM7:TR?=M2HDfnNCVkeHUh?=
MZ7-melNEe1[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfjSmc3UUN3ME2xOU4yODZ5IN88US=>NYfKT2VbW0GQR1XS
TE-5MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjMfXNKSzVyPUG1MlI{OzNizszNMnnnV2FPT0WU
647-VMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHNT3BqUUN3ME2xOU4zPzB3IN88US=>MlqzV2FPT0WU
DMS-114Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLmdopjUUN3ME2xOU4{OjlzIN88US=>NV;hRWF2W0GQR1XS
ME-180MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTF3LkS3PFMh|ryPM37PbnNCVkeHUh?=
MS-1M{PjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3LWHo3UUN3ME2xOU42PjJ|IN88US=>MWHTRW5ITVJ?
NUGC-3MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jHPGlEPTB;MUWuOlI1PSEQvF2=NIjuT2VUSU6JRWK=
GB-1NXPaPJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTtTWM2OD1zNT62OFM4KM7:TR?=MUDTRW5ITVJ?
LOXIMVIMmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPUNlRKSzVyPUG1Mlg6OTlizszNMXvTRW5ITVJ?
NCI-H1304MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjxTWM2OD1zNT64PVI5KM7:TR?=NF\OPG1USU6JRWK=
KURAMOCHIMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELnN3pKSzVyPUG1Mlk4OSEQvF2=NVPJS2dZW0GQR1XS
SW1783MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnrTWM2OD1zNj6wPVk{KM7:TR?=NVTaNFhCW0GQR1XS
EGI-1NV;EUGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjpbHhKSzVyPUG2MlU{PjVizszNNUTpTmltW0GQR1XS
KGNNF[2XpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4L2RmlEPTB;MU[uOVU5PiEQvF2=M2TsWXNCVkeHUh?=
PANC-03-27MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTF4Lke2OlIh|ryPMkDWV2FPT0WU
RH-1Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmGwTWM2OD1zNj64NlUh|ryPM{\RUnNCVkeHUh?=
HT-1376M37NZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPRe2JKSzVyPUG2Mlg1PDZizszNMWDTRW5ITVJ?
ZR-75-30MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3kcYE1UUN3ME2xOk46OzZzIN88US=>NXq5Nop3W0GQR1XS
TI-73M4DjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTF4Lkm0NFgh|ryPM1L4dnNCVkeHUh?=
TK10NVfUb|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjBSWJKSzVyPUG3MlAxPzlizszNMWfTRW5ITVJ?
SW684Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLoTWM2OD1zNz6wNVU1KM7:TR?=MWrTRW5ITVJ?
RPMI-8866Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTF5LkC2PVkh|ryPNFm0TFlUSU6JRWK=
LNCaP-Clone-FGCNX3US45HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HHb2lEPTB;MUeuOVIxOSEQvF2=M{Xld3NCVkeHUh?=
NCI-H2291MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\EUnlKSzVyPUG4MlQ{PDVizszNNIfDN3VUSU6JRWK=
T47DMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrmUHlVUUN3ME2xPE41QDhizszNMWnTRW5ITVJ?
A204NWHOZVFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoL4TWM2OD1zOD61OFUzKM7:TR?=M3;MdHNCVkeHUh?=
HT-144NFO3U4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE[ybm9KSzVyPUG4Mlc1OjdizszNNGTOcoVUSU6JRWK=
MDA-MB-361MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWW1eYQ3UUN3ME2xPU4xPzF2IN88US=>MkewV2FPT0WU
HCC1806Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTF7LkG1PVEh|ryPNWG1SodLW0GQR1XS
NCI-H596Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jyTWlEPTB;MUmuOlM6OSEQvF2=MonJV2FPT0WU
K-562NXzsZZdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXL[FNKSzVyPUG5Mlg6OjZizszNM1HyZ3NCVkeHUh?=
D-336MGMlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnDW29KSzVyPUG5Mlk{OjJizszNNIPHTlJUSU6JRWK=
SK-MEL-2NIHIN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTwZmp2UUN3ME2yNE4yPTV7IN88US=>MmH5V2FPT0WU
HEC-1M3\lVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTqeGdKSzVyPUKwMlQ6PzhizszNM2LrOXNCVkeHUh?=
EW-13M3\iU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlr4TWM2OD1{MD61OFQ{KM7:TR?=MkD6V2FPT0WU
Hs-578-TM2TY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NES0ToVKSzVyPUKwMlU2QDNizszNM13sb3NCVkeHUh?=
SJSA-1NGr5WmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJyLkW2PFgh|ryPNY\pR4FxW0GQR1XS
RCC10RGBM{\qfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWGzcoZmUUN3ME2yNE43PzF7IN88US=>NInWcJlUSU6JRWK=
LAN-6NGq1WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jtcWlEPTB;MkGuNFM6PiEQvF2=NVL3dGt3W0GQR1XS
NCI-H1048MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\mTWM2OD1{MT6yNlU5KM7:TR?=NInMRXVUSU6JRWK=
CW-2NVzyRWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTJzLkK3NFUh|ryPM3\oWnNCVkeHUh?=
HCC2157NF\LOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\PTWM2OD1{MT6zOkDPxE1?NXHnN4J7W0GQR1XS
EW-22NXzyclJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;NXmlEPTB;MkGuN|c3KM7:TR?=MXLTRW5ITVJ?
A253M1P3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jhT2lEPTB;MkGuOFQ5OSEQvF2=M4nQcnNCVkeHUh?=
BE-13M{W4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo[5TWM2OD1{MT62NVE{KM7:TR?=Mm\CV2FPT0WU
KINGS-1MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2qweWlEPTB;MkGuOlMyPiEQvF2=MmTWV2FPT0WU
ETK-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DPcmlEPTB;MkGuPFE2OiEQvF2=MoeyV2FPT0WU
NCI-H2452M1zyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DvWWlEPTB;MkGuPFY1PyEQvF2=M{G1enNCVkeHUh?=
HPAF-IIMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXP5[|BbUUN3ME2yNU45QTJ|IN88US=>Mnf3V2FPT0WU
D-542MGNULsN3p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXnTWM2OD1{MT65NFY6KM7:TR?=MWfTRW5ITVJ?
NCI-H630NGnRSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIiz[5RKSzVyPUKyMlAzQTZizszNMYrTRW5ITVJ?
TGBC11TKBNFKxSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTjbHlKSzVyPUKyMlA1QSEQvF2=M4j6OXNCVkeHUh?=
BCPAPMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3tTWM2OD1{Mj62NVEh|ryPM1nmUXNCVkeHUh?=
HLENYTmfplQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTJ{Lk[5O{DPxE1?NYjzd4QzW0GQR1XS
NCI-H727MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUC2VHdPUUN3ME2yNk44OzVizszNNX65PVA3W0GQR1XS
RDNEjVc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfVPY1KSzVyPUKyMlc2OThizszNNW\DOoxPW0GQR1XS
NCI-H522MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTJ{Lki0N|Eh|ryPNHvOboVUSU6JRWK=
CGTH-W-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3DVZZKSzVyPUKzMlA3PDFizszNNWTtXIViW0GQR1XS
SK-LU-1NEfjNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTJ|LkS2PFMh|ryPNHzCSGlUSU6JRWK=
BB65-RCCNH7ub5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEno[WVKSzVyPUKzMlc5PjNizszNMV\TRW5ITVJ?
HSC-3MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XUWWlEPTB;MkOuPFUzPyEQvF2=NH2zOZRUSU6JRWK=
SK-MES-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjSTWM2OD1{ND6wNVYyKM7:TR?=Ml7BV2FPT0WU
DBNVW3SGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrhTWM2OD1{ND6xNFI5KM7:TR?=MoHhV2FPT0WU
HO-1-N-1M2TsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTJ2LkOwPVMh|ryPM4X2TnNCVkeHUh?=
MKN1NFj6b5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjNVWxTUUN3ME2yOE43QCEQvF2=MV;TRW5ITVJ?
MN-60NGDSXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEK1SG9KSzVyPUK0Mlg2OTlizszNM2PkZXNCVkeHUh?=
8505CMkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTJ3LkG4OFUh|ryPMnf5V2FPT0WU
COLO-320-HSRMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXl[ZpKSzVyPUK1MlIzODhizszNNWTJdFBvW0GQR1XS
BB30-HNCM2DNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37US2lEPTB;MkWuNlQ5OyEQvF2=MV7TRW5ITVJ?
KM12NH;3Xm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LQRWlEPTB;MkWuOVgxPyEQvF2=MlPBV2FPT0WU
NB13NHG3OYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTJ3LkW4PVgh|ryPMXvTRW5ITVJ?
HCC2998MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTJ4LkCyPFMh|ryPM4rOS3NCVkeHUh?=
U-118-MGMlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLoTWM2OD1{Nj6wPFA5KM7:TR?=Mnj2V2FPT0WU
NB10M4XGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHuyfYNKSzVyPUK2MlI{PCEQvF2=MYPTRW5ITVJ?
SK-LMS-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLtTWM2OD1{Nz6wO|A1KM7:TR?=MkfXV2FPT0WU
SW1573NVP3bo05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTJ5LkGxJO69VQ>?MWXTRW5ITVJ?
LB373-MEL-DMmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzs[opKSzVyPUK3MlEzQTRizszNMVPTRW5ITVJ?
DK-MGNEOzfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzEb3VZUUN3ME2yO{4yQDF5IN88US=>MmfaV2FPT0WU
RMG-IMl30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVP6[pZqUUN3ME2yO{4zODJ7IN88US=>M2TUPXNCVkeHUh?=
SW1088MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTJ5LkWwOFIh|ryPM1jmXHNCVkeHUh?=
SK-OV-3M3Piemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmj6TWM2OD1{Nz63OVk{KM7:TR?=M1iyd3NCVkeHUh?=
KP-N-YNMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXGNGtKSzVyPUK3MlgxPDNizszNNGKzNGhUSU6JRWK=
RPMI-7951NV;1fmNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXtTWM2OD1{OD6yOFU3KM7:TR?=M1rESnNCVkeHUh?=
CaR-1MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTJ6LkW1PFIh|ryPM2nrZXNCVkeHUh?=
MKN7MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTNTWM2OD1{OD61PVY1KM7:TR?=MoOzV2FPT0WU
CHP-212MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoriTWM2OD1{OD63OFAyKM7:TR?=M4LwSXNCVkeHUh?=
KYSE-450MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzYfZZGUUN3ME2yPE45ODlzIN88US=>MUHTRW5ITVJ?
RXF393MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\PcWNKSzVyPUK5MlI6ODZizszNNGLnXWhUSU6JRWK=
P30-OHKM1nCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrUZZZKSzVyPUK5MlMxPDhizszNNX3BT4tQW0GQR1XS
Ca9-22M{CyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDmWopKSzVyPUK5MlQzQTlizszNNFHxTGdUSU6JRWK=
RT-112MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHMVoxDUUN3ME2yPU41PjFzIN88US=>NHq1PVZUSU6JRWK=
ES1MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LwWmlEPTB;MkmuPFU1PCEQvF2=MXXTRW5ITVJ?
HCE-4NEnKb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvwU4ZJUUN3ME2yPU45Pzh4IN88US=>NEXifXhUSU6JRWK=
AM-38M1Ptb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTNyLkC2NFYh|ryPM4rQOXNCVkeHUh?=
AsPC-1NIe1OlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTNyLkiwOVMh|ryPNHfId2VUSU6JRWK=
TE-9MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzU[5lFUUN3ME2zNE45PzN5IN88US=>NH;0S4pUSU6JRWK=
HuP-T4NWDzWIg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TkfmlEPTB;M{CuPVY{QCEQvF2=NGDFN|FUSU6JRWK=
LB2518-MELMnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PWbWlEPTB;M{GuNFc1PCEQvF2=Mk\1V2FPT0WU
NCI-H1703MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnYTWM2OD1|MT6wPVA2KM7:TR?=MoLWV2FPT0WU
NCI-H2228MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGK5S5NKSzVyPUOxMlQ3PTFizszNNWLm[2x2W0GQR1XS
SCC-4MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;qO2lEPTB;M{GuPVE5OSEQvF2=M2XIN3NCVkeHUh?=
KNS-81-FDNVH0fZRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkG3TWM2OD1|Mj6wNVI5KM7:TR?=NGDBVZdUSU6JRWK=
NTERA-S-cl-D1NEe5R4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXnSGxFUUN3ME2zNk4xPzN7IN88US=>MYjTRW5ITVJ?
DaoyMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4GxZmlEPTB;M{KuNFg{QCEQvF2=NWXSUlAxW0GQR1XS
ES4NWr3cnNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2raOmlEPTB;M{KuN|kzOiEQvF2=NGrTWnlUSU6JRWK=
MHH-ES-1MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHnTWM2OD1|Mj60PFczKM7:TR?=NHi5[plUSU6JRWK=
C-33-ANYDUflNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jtTmlEPTB;M{KuO|czQCEQvF2=Mm\zV2FPT0WU
BHYNXP6RZNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvFTZdKSzVyPUOyMlk1QTVizszNNVO0enhFW0GQR1XS
Detroit562NXTCXIV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHG3VYxKSzVyPUOzMlY3PTdizszNNHHqPJNUSU6JRWK=
EW-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHoZYZ4UUN3ME2zN{46OzJ{IN88US=>NGPXfVZUSU6JRWK=
NCI-H1395NUfs[FJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfaTWM2OD1|ND6wO|k6KM7:TR?=NH\MS3JUSU6JRWK=
KM-H2NXLnfWJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33v[mlEPTB;M{[uOFc1OyEQvF2=MVvTRW5ITVJ?
NCI-H520NVvBUVh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTN4Lke1OFEh|ryPNFroSZZUSU6JRWK=
D-392MGMnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTN5LkOzOFQh|ryPNG\ITXlUSU6JRWK=
NOMO-1MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTETWM2OD1|Nz64NFg6KM7:TR?=NGPp[pRUSU6JRWK=
TE-6M1T6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\iTFFKSzVyPUO4MlEzPCEQvF2=M1jVdnNCVkeHUh?=
HT-3MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTN6LkS0N|Yh|ryPNGKzUoJUSU6JRWK=
RPMI-8226M1jQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXWTWM2OD1|OD65OVE6KM7:TR?=Ml61V2FPT0WU
U251NFXHSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXvRllRUUN3ME2zPU4xOTJ2IN88US=>NY[4b|ZlW0GQR1XS
GCTM1TIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Dz[WlEPTB;M{muNVg2OiEQvF2=MlPsV2FPT0WU
A431MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTN7LkG4PVQh|ryPNIfEd29USU6JRWK=
TE-12NXjNPZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTN7LkK0OFgh|ryPMUfTRW5ITVJ?
HMV-IINGLvV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLSN3E6UUN3ME2zPU42ODR5IN88US=>NFXjWIpUSU6JRWK=
IST-MES1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILObpRKSzVyPUSwMlE2ODJizszNMXLTRW5ITVJ?
SW13NIHTdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYX5coRvUUN3ME20NE42OTlizszNMlTKV2FPT0WU
SF295NVruNFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7VVJVKSzVyPUSwMlgxPjZizszNNYXQRoRWW0GQR1XS
MDA-MB-157NIftXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTRyLkm0OlIh|ryPMnfjV2FPT0WU
TE-1NXXpRphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T1dmlEPTB;NEGuPFcyPCEQvF2=MkDNV2FPT0WU
HuCCT1Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPEb5loUUN3ME20Nk42Ojh7IN88US=>MoD6V2FPT0WU
KYSE-510NYfhZ4xHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUn4doZGUUN3ME20N{4yPzV2IN88US=>NF\3VVlUSU6JRWK=
NCI-H358NGrXOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nmNWlEPTB;NESuNFMxPCEQvF2=NFHnR5VUSU6JRWK=
SW900MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfQTWM2OD12ND6wO|U5KM7:TR?=MYHTRW5ITVJ?
CAS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PKPWlEPTB;NESuNFk6OSEQvF2=NWfweIhwW0GQR1XS
TE-8MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknPTWM2OD12ND61OlU5KM7:TR?=MVrTRW5ITVJ?
P12-ICHIKAWANX:1XWRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vRe2lEPTB;NESuOlEyOiEQvF2=NWrQU3VtW0GQR1XS
YKG-1NIHERldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TXbmlEPTB;NESuO|gyKM7:TR?=NWTlVGhsW0GQR1XS
SNU-C2BMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHkV4xtUUN3ME20OE44QTB|IN88US=>MlTNV2FPT0WU
LCLC-103HNXH2[lk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;iTWM2OD12ND64O|A{KM7:TR?=NYXaPWo5W0GQR1XS
U-87-MGNXTucHFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTR3LkGwNlIh|ryPM2WzVHNCVkeHUh?=
HAL-01M4XKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTR3LkGzO|kh|ryPM1PKZnNCVkeHUh?=
OVCAR-8MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LvTGlEPTB;NEWuN|U3PCEQvF2=NVvybmN4W0GQR1XS
KYSE-150M3q0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrNTWRsUUN3ME20O{4yODV{IN88US=>Ml;hV2FPT0WU
OE33NYrSV5ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTR5LkG0Nlkh|ryPM4LxWXNCVkeHUh?=
CAL-62MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXv3UlBtUUN3ME20O{41ODZ6IN88US=>NF7MXYpUSU6JRWK=
TCCSUPNEHiVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3r1TGlEPTB;NEeuOlI3PCEQvF2=M1GyNnNCVkeHUh?=
H4M3PNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MluyTWM2OD12Nz62OlIyKM7:TR?=MX;TRW5ITVJ?
CP66-MELMkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITBbJVKSzVyPUS4MlA4ODRizszNM4Lxd3NCVkeHUh?=
SNB75M3X2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\xVWlEPTB;NEiuNVg4PCEQvF2=NIjVPVBUSU6JRWK=
Mo-TNV;S[IpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTR6LkK3PUDPxE1?MmC3V2FPT0WU
BT-549M4Xubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTR6LkO3Nlkh|ryPMnvCV2FPT0WU
IGR-1MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jJZWlEPTB;NEiuOlY1PSEQvF2=NX3nRlVxW0GQR1XS
NCI-H1299NGW5N2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;rSWlEPTB;NEiuO|I1QCEQvF2=MWXTRW5ITVJ?
ALL-POM4m2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTR7LkmyOlgh|ryPMkizV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. [2]
Features

Protocol(Only for Reference)

Cell Assay: [2]

Cell lines SW620, LoVo, V3-YAC and V3 cells
Concentrations 0.5 μM or 1 μM
Incubation Time 17 hours
Method The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min 137Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 105 per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

Animal Study: [2]

Animal Models Female rude mice bearing SW620 xenografts
Formulation Sterile 0.9% sodium chloride solution
Dosages 10 mg/kg
Administration Intraperitoneally administrated

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Leahy JJ, et al. Bioorg Med Chem Lett, 2004, 14(24), 6083-6087.

[2] Zhao Y, et al. Cancer Res, 2006 , 66(10), 5354-5362.

view more

Chemical Information

Download NU7441 (KU-57788) SDF
Molecular Weight (MW) 413.49
Formula

C25H19NO3S

CAS No. 503468-95-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL (7.25 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4H-1-Benzopyran-4-one, 8-(4-dibenzothienyl)-2-(4-morpholinyl)-

Customer Product Validation(4)


Click to enlarge
Rating
Source Nucleic Acids Res 2013 41(15), 7378-86. NU7441 (KU-57788) purchased from Selleck
Method EU Immunofluorescence
Cell Lines A2780 ovarian cancer cells
Concentrations 1 uM
Incubation Time 1 h
Results It performed similar experiments using specific inhibitors of DNA-PK. Treatment with Nu7026 or Nu7441 before cisplatin significantly prevented inhibition of rRNA synthesis.

Click to enlarge
Rating
Source Nucleic Acids Res 2013 41, 10157-69. NU7441 (KU-57788) purchased from Selleck
Method Confocal immunostaining
Cell Lines 293T
Concentrations
Incubation Time 30min ,60min
Results the number of IRIFs was reduced significantly in p18CycE-expressing HEK 293T cells compared with parental cells. Pharmacological inhibition of ATM with KU55933 Revealed that S25-53BP1 phosphorylation was ATM-dependent in these cells as IRIFs of S25-53BP1 were abolished in both parental, as well as p18CycE-expressing cells.

Click to enlarge
Rating
Source Toxicol Sci 2014 10.1093/toxsci/kfu207. NU7441 (KU-57788) purchased from Selleck
Method Western blot
Cell Lines H460 cells
Concentrations 1, 3, 10 uM
Incubation Time 1 h
Results It tested 3 concentrations of 2 DNAPK inhibitors (NU7026 and NU7441) for their off-target effects on ATM and ATR signaling in camptothecin-exposed cells. We found that only the highest dose of 60 uM NU7026 clearly diminished ATR activity as evidenced by a lower CHK1 phosphorylation. All doses of both inhibitors eliminated activating autophosphorylation of DNAPK at Ser2056.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. NU7441 (KU-57788) purchased from Selleck
Method
Cell Lines A549 cells
Concentrations 0-10 μM
Incubation Time 3 h
Results NU-7441 treatment resulted in a reduction of AKT phosphorylation.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA-PK Products

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • NU7026

    NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

  • KU-0060648

    KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Recently Viewed Items

Tags: buy NU7441 (KU-57788) | NU7441 (KU-57788) supplier | purchase NU7441 (KU-57788) | NU7441 (KU-57788) cost | NU7441 (KU-57788) manufacturer | order NU7441 (KU-57788) | NU7441 (KU-57788) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us